Home / Brands / King Legacy, a wholly owned subsidiary of Pfizer
King Legacy, a wholly owned subsidiary of Pfizer Recalls
11 recalls on record · May 29, 2013 to May 29, 2013 · Drugs
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-count bottles (NDC 60793-859-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-count bottles (NDC 60793-857-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-count bottles (NDC 60793-856-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-co
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-cou
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-cou
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-cou
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.
May 29, 2013DrugsFDA
King Legacy, a wholly owned subsidiary of Pfizer recalls Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-cou
Hazard: Subpotent Drug: The products were below specification for potency at the expiry stability point.